NOT FOR DISTRIBUTION
Header cover image

Market Cap

Rp529.7b

Last Updated

2021/05/11 10:20 UTC

Data Sources

Company Financials

Executive Summary

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Pyridam Farma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PYFA is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: PYFA's weekly volatility has decreased from 13% to 7% over the past year.


Market Performance


7 Day Return

-7.9%

PYFA

0.4%

ID Pharmaceuticals

0.1%

ID Market


1 Year Return

342.0%

PYFA

21.6%

ID Pharmaceuticals

27.1%

ID Market

Return vs Industry: PYFA exceeded the ID Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: PYFA exceeded the ID Market which returned 22.3% over the past year.


Shareholder returns

PYFAIndustryMarket
7 Day-7.9%0.4%0.1%
30 Day-3.9%-3.5%-1.8%
90 Day-2.0%-8.2%-4.4%
1 Year342.0%342.0%23.9%21.6%31.4%27.1%
3 Year437.7%426.6%5.9%-0.02%7.5%-0.6%
5 Year783.7%753.4%33.7%21.1%38.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Pyridam Farma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pyridam Farma undervalued compared to its fair value and its price relative to the market?

25.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PYFA (IDR990) is trading above our estimate of fair value (IDR60.89)

Significantly Below Fair Value: PYFA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PYFA is poor value based on its PE Ratio (25.8x) compared to the ID Pharmaceuticals industry average (25x).

PE vs Market: PYFA is poor value based on its PE Ratio (25.8x) compared to the ID market (22.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PYFA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PYFA is overvalued based on its PB Ratio (3.8x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Pyridam Farma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pyridam Farma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Pyridam Farma performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PYFA has high quality earnings.

Growing Profit Margin: PYFA's current net profit margins (8%) are higher than last year (3.6%).


Past Earnings Growth Analysis

Earnings Trend: PYFA's earnings have grown significantly by 30.2% per year over the past 5 years.

Accelerating Growth: PYFA's earnings growth over the past year (126.4%) exceeds its 5-year average (30.2% per year).

Earnings vs Industry: PYFA earnings growth over the past year (126.4%) exceeded the Pharmaceuticals industry 9%.


Return on Equity

High ROE: PYFA's Return on Equity (14.6%) is considered low.


Financial Health

How is Pyridam Farma's financial position?


Financial Position Analysis

Short Term Liabilities: PYFA's short term assets (IDR124.5B) exceed its short term liabilities (IDR36.9B).

Long Term Liabilities: PYFA's short term assets (IDR124.5B) exceed its long term liabilities (IDR40.9B).


Debt to Equity History and Analysis

Debt Level: PYFA's debt to equity ratio (14.3%) is considered satisfactory.

Reducing Debt: PYFA's debt to equity ratio has reduced from 42.7% to 14.3% over the past 5 years.

Debt Coverage: PYFA's debt is well covered by operating cash flow (36.6%).

Interest Coverage: PYFA's interest payments on its debt are well covered by EBIT (15x coverage).


Balance Sheet


Dividend

What is Pyridam Farma current dividend yield, its reliability and sustainability?

0.40%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PYFA's dividend (0.4%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.15%).

High Dividend: PYFA's dividend (0.4%) is low compared to the top 25% of dividend payers in the ID market (4.83%).


Stability and Growth of Payments

Stable Dividend: PYFA is not paying a notable dividend for the ID market, therefore no need to check if payments are stable.

Growing Dividend: PYFA is not paying a notable dividend for the ID market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PYFA's dividend in 3 years as they are not forecast to pay a notable one for the ID market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Michael Handoko Soetrisno (57 yo)

20.42yrs

Tenure

Mr. Michael Handoko Boedi Soetrisno has been the President Director at PT Pyridam Farma Tbk since December 2000 and its Director since 1996. He served as Director of Manufacture at PT Pyridam Farma Tbk. He...


Leadership Team

Experienced Management: PYFA's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: PYFA's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Pyridam Farma Tbk's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Pyridam Farma Tbk
  • Ticker: PYFA
  • Exchange: IDX
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp529.729b
  • Shares outstanding: 535.08m
  • Website: https://www.pyridam.com

Number of Employees


Location

  • PT Pyridam Farma Tbk
  • Ruko Villa Kebon Jeruk
  • Blok F3
  • Jakarta
  • 11530
  • Indonesia

Listings


Biography

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/11 10:20
End of Day Share Price2021/05/10 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.